TCMD
TACTILE SYSTEMS TECHNOLOGY INC
+0.16 (+0.72%)22.33USD86.3K成交股數506M市值20.9本益比(近四季)1.4股價營收比+8.6%營收年增(近四季)2026-11-02下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 1 · 323K · 1 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 437K |
| 近 180 天 淨額 | −437K |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | 08-12 | Dodd Sheri Louise | Chief Executive Officer | S 公開市場賣出 | 11.0K | 29.44 | 323K | 233K | SEC |
| 2026-05-11 | 05-13 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | S 公開市場賣出 | 4.6K | 24.49 | 113K | 130K | SEC |
| 2026-05-06 | 05-08 | Volkart Carmen B | Director | A 獲配股票 | 6.5K | – | – | 44.2K | SEC |
| 2026-05-06 | 05-08 | Huggenberger Raymond | Director | A 獲配股票 | 6.5K | – | – | 62.8K | SEC |
| 2026-05-06 | 05-08 | Asbury Valerie L. | Director | A 獲配股票 | 6.5K | – | – | 55.3K | SEC |
| 2026-05-06 | 05-08 | BURKE WILLIAM W | Director | A 獲配股票 | 6.5K | – | – | 55.0K | SEC |
| 2026-05-06 | 05-08 | Shafer David Brent | Director | A 獲配股票 | 6.5K | – | – | 55.3K | SEC |
| 2026-05-06 | 05-08 | Pearson Andrea | Director | A 獲配股票 | 6.5K | – | – | 7.4K | SEC |
| 2026-05-06 | 05-08 | Washington Boyd Vindell | Director | A 獲配股票 | 6.5K | – | – | 41.8K | SEC |
| 2026-05-06 | 05-08 | King Laura G. | Director | A 獲配股票 | 6.5K | – | – | 25.6K | SEC |
| 2026-03-09 | 03-11 | Pearson Andrea | Director | A 獲配股票 | 852 | – | – | 852 | SEC |
| 2026-02-24 | 02-26 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S 公開市場賣出 | 6.2K | 28.94 | 181K | 82.6K | SEC |
| 2026-02-24 | 02-26 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | S 公開市場賣出 | 7.7K | 28.94 | 223K | 135K | SEC |
| 2026-02-24 | 02-26 | Dodd Sheri Louise | Chief Executive Officer | S 公開市場賣出 | 11.0K | 28.94 | 318K | 244K | SEC |
| 2026-02-23 | 02-24 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | S 公開市場賣出 | 5.3K | 28.28 | 151K | 143K | SEC |
| 2026-02-23 | 02-24 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | S 公開市場賣出 | 196 | 28.69 | 6K | 143K | SEC |
| 2026-02-23 | 02-24 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S 公開市場賣出 | 4.3K | 28.28 | 121K | 89.0K | SEC |
| 2026-02-23 | 02-24 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S 公開市場賣出 | 160 | 28.69 | 5K | 88.8K | SEC |
| 2026-02-23 | 02-24 | Dodd Sheri Louise | Chief Executive Officer | S 公開市場賣出 | 14.7K | 28.28 | 416K | 255K | SEC |
| 2026-02-23 | 02-24 | Dodd Sheri Louise | Chief Executive Officer | S 公開市場賣出 | 537 | 28.69 | 15K | 255K | SEC |
| 2026-02-20 | 02-24 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | A 獲配股票 | 3.6K | – | – | 126K | SEC |
| 2026-02-20 | 02-24 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | A 獲配股票 | 15.6K | – | – | 148K | SEC |
| 2026-02-20 | 02-24 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | A 獲配股票 | 6.8K | – | – | 132K | SEC |
| 2026-02-20 | 02-24 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A 獲配股票 | 7.1K | – | – | 93.3K | SEC |
| 2026-02-20 | 02-24 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A 獲配股票 | 4.1K | – | – | 86.1K | SEC |
| 2026-02-20 | 02-24 | Dodd Sheri Louise | Chief Executive Officer | A 獲配股票 | 19.8K | – | – | 242K | SEC |
| 2026-02-20 | 02-24 | Dodd Sheri Louise | Chief Executive Officer | A 獲配股票 | 28.2K | – | – | 270K | SEC |
| 2026-02-20 | 02-24 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A 獲配股票 | 3.5K | – | – | 82.1K | SEC |
| 2026-02-19 | 02-23 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | A 獲配股票 | 23.0K | – | – | 122K | SEC |
| 2026-02-19 | 02-23 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A 獲配股票 | 6.2K | – | – | 78.6K | SEC |
| 2026-02-19 | 02-23 | Dodd Sheri Louise | Chief Executive Officer | A 獲配股票 | 48.7K | – | – | 222K | SEC |
| 2026-01-02 | 01-06 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S 公開市場賣出(10b5-1) | 5.1K | 28.85 | 148K | 72.4K | SEC |
| 2025-08-08 | 08-12 | Dodd Sheri Louise | Chief Executive Officer | S 公開市場賣出 | 7.8K | 12.36 | 96K | 173K | SEC |
| 2025-05-12 | 05-14 | Birkemeyer Elaine M. | Chief Financial Officer | S 公開市場賣出(10b5-1) | 2.9K | 9.94 | 29K | 99.1K | SEC |
| 2025-05-08 | 05-12 | Dodd Sheri Louise | Chief Executive Officer | S 公開市場賣出 | 3.1K | 9.83 | 31K | 181K | SEC |
| 2025-05-08 | 05-09 | BURKE WILLIAM W | Director | S 公開市場賣出(10b5-1) | 3.3K | 9.67 | 32K | 48.5K | SEC |
| 2025-05-07 | 05-09 | Volkart Carmen B | Director | A 獲配股票 | 16.1K | – | – | 37.7K | SEC |
| 2025-05-07 | 05-09 | Washington Boyd Vindell | Director | A 獲配股票 | 16.1K | – | – | 35.2K | SEC |
| 2025-05-07 | 05-09 | Huggenberger Raymond | Director | A 獲配股票 | 16.1K | – | – | 56.3K | SEC |
| 2025-05-07 | 05-09 | BURKE WILLIAM W | Director | A 獲配股票 | 16.1K | – | – | 51.8K | SEC |
| 2025-05-07 | 05-09 | Asbury Valerie L. | Director | A 獲配股票 | 16.1K | – | – | 48.8K | SEC |
| 2025-05-07 | 05-09 | King Laura G. | Director | A 獲配股票 | 16.1K | – | – | 19.0K | SEC |
| 2025-05-07 | 05-09 | Shafer David Brent | Director | A 獲配股票 | 16.1K | – | – | 48.8K | SEC |
| 2025-03-11 | 03-13 | REUVERS DANIEL L. | Director | G 贈與 | 68.2K | – | – | 68.2K | SEC |
| 2025-03-11 | 03-13 | REUVERS DANIEL L. | Director | G 贈與 | 68.2K | – | – | 146K | SEC |
| 2025-02-25 | 02-27 | Birkemeyer Elaine M. | Chief Financial Officer | S 公開市場賣出(10b5-1) | 2.1K | 14.51 | 30K | 102K | SEC |
| 2025-02-25 | 02-27 | REUVERS DANIEL L. | Director | S 公開市場賣出(10b5-1) | 28.3K | 14.18 | 402K | 215K | SEC |
| 2025-02-25 | 02-27 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S 公開市場賣出 | 6.5K | 14.40 | 93K | 77.5K | SEC |
| 2025-02-24 | 02-24 | REUVERS DANIEL L. | Director | S 公開市場賣出(10b5-1) | 10.9K | 14.55 | 159K | 243K | SEC |
| 2025-02-24 | 02-24 | Birkemeyer Elaine M. | Chief Financial Officer | S 公開市場賣出(10b5-1) | 3.8K | 14.70 | 56K | 104K | SEC |
| 2025-02-24 | 02-24 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S 公開市場賣出 | 4.8K | 14.65 | 71K | 84.0K | SEC |
| 2025-02-20 | 02-24 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A 獲配股票 | 3.4K | – | – | 68.1K | SEC |
| 2025-02-20 | 02-24 | Dodd Sheri Louise | Chief Executive Officer | A 獲配股票 | 65.7K | – | – | 184K | SEC |
| 2025-02-20 | 02-24 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A 獲配股票 | 16.6K | – | – | 88.8K | SEC |
| 2025-02-20 | 02-24 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A 獲配股票 | 4.1K | – | – | 72.3K | SEC |
| 2025-02-20 | 02-24 | Dodd Sheri Louise | Chief Executive Officer | A 獲配股票 | 20.1K | – | – | 119K | SEC |
| 2025-02-20 | 02-24 | Birkemeyer Elaine M. | Chief Financial Officer | A 獲配股票 | 36.2K | – | – | 108K | SEC |
| 2025-02-20 | 02-24 | Birkemeyer Elaine M. | Chief Financial Officer | A 獲配股票 | 6.9K | – | – | 71.6K | SEC |
| 2025-02-20 | 02-24 | Birkemeyer Elaine M. | Chief Financial Officer | A 獲配股票 | 3.4K | – | – | 64.7K | SEC |
| 2025-02-20 | 02-24 | King Laura G. | Director | A 獲配股票 | 3.0K | – | – | 3.0K | SEC |
| 2025-02-20 | 02-24 | REUVERS DANIEL L. | Director | A 獲配股票 | 15.9K | – | – | 254K | SEC |
| 2024-08-12 | 08-14 | Ferstler Sherri Lee | Senior VP, Sales | S 公開市場賣出 | 1.6K | 13.07 | 20K | 38.8K | SEC |
| 2024-08-07 | 08-09 | Dodd Sheri Louise | Chief Executive Officer | A 獲配股票 | 65.0K | – | – | 98.6K | SEC |
| 2024-05-16 | 05-20 | Birkemeyer Elaine M. | Chief Financial Officer | S 公開市場賣出 | 3.0K | 13.68 | 42K | 61.3K | SEC |
| 2024-05-08 | 05-10 | Washington Boyd Vindell | Director | A 獲配股票 | 10.5K | – | – | 19.2K | SEC |
| 2024-05-08 | 05-10 | BURKE WILLIAM W | Director | A 獲配股票 | 10.5K | – | – | 35.7K | SEC |
| 2024-05-08 | 05-10 | Shafer David Brent | Director | A 獲配股票 | 10.5K | – | – | 32.7K | SEC |
| 2024-05-08 | 05-10 | Volkart Carmen B | Director | A 獲配股票 | 10.5K | – | – | 21.6K | SEC |
| 2024-05-08 | 05-10 | BURKE WILLIAM W | Director | S 公開市場賣出(10b5-1) | 2.5K | 14.06 | 35K | 25.3K | SEC |
| 2024-05-08 | 05-10 | Asbury Valerie L. | Director | A 獲配股票 | 10.5K | – | – | 32.7K | SEC |
| 2024-05-08 | 05-10 | Dodd Sheri Louise | Director | A 獲配股票 | 10.5K | – | – | 33.7K | SEC |
| 2024-05-08 | 05-10 | Huggenberger Raymond | Director | A 獲配股票 | 10.5K | – | – | 40.2K | SEC |
| 2024-05-06 | 05-08 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S 公開市場賣出 | 815 | 14.37 | 12K | 62.6K | SEC |
| 2024-02-29 | 02-29 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S 公開市場賣出(10b5-1) | 243 | 15.25 | 4K | 63.4K | SEC |
| 2024-02-29 | 02-29 | REUVERS DANIEL L. | President and CEO | S 公開市場賣出(10b5-1) | 1.4K | 15.25 | 21K | 238K | SEC |
| 2024-02-27 | 02-29 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S 公開市場賣出(10b5-1) | 1.1K | 15.58 | 17K | 63.6K | SEC |
| 2024-02-27 | 02-29 | REUVERS DANIEL L. | President and CEO | S 公開市場賣出(10b5-1) | 4.7K | 15.60 | 73K | 239K | SEC |
| 2024-02-26 | 02-27 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | S 公開市場賣出(10b5-1) | 2.0K | 15.91 | 32K | 63.5K | SEC |
| 2024-02-26 | 02-27 | REUVERS DANIEL L. | President and CEO | S 公開市場賣出(10b5-1) | 6.2K | 15.81 | 99K | 244K | SEC |
| 2024-02-24 | 02-27 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | A 獲配股票 | 9.0K | – | – | 62.8K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| BlackRock, Inc. | 1.9M | 56.7M | 新進 | 新進 |
| CADIAN CAPITAL MANAGEMENT, LP | 1.6M | 47.0M | 新進 | 新進 |
| DIMENSIONAL FUND ADVISORS LP | 1.1M | 32.5M | 新進 | 新進 |
| MORGAN STANLEY | 979K | 29.2M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 970K | 28.9M | 新進 | 新進 |
| Driehaus Capital Management LLC | 938K | 27.9M | 新進 | 新進 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 707K | 21.0M | 新進 | 新進 |
| FEDERATED HERMES, INC. | 681K | 20.3M | 新進 | 新進 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 638K | 19.0M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 586K | 17.5M | 新進 | 新進 |
| STATE STREET CORP | 576K | 17.2M | 新進 | 新進 |
| NEXT CENTURY GROWTH INVESTORS LLC | 480K | 14.3M | 新進 | 新進 |
| 文藝復興 RENAISSANCE TECHNOLOGIES LLC | 474K | 14.1M | 新進 | 新進 |
| First Light Asset Management, LLC | 463K | 13.8M | 新進 | 新進 |
| Jupiter Topco LLC | 397K | 11.8M | 新進 | 新進 |
| PINNACLE ASSOCIATES LTD | 327K | 9.7M | 新進 | 新進 |
| PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. | 315K | 9.4M | 新進 | 新進 |
| Dana Investment Advisors, Inc. | 306K | 9.1M | 新進 | 新進 |
| AMERICAN CENTURY COMPANIES INC | 268K | 8.0M | 新進 | 新進 |
| AMERIPRISE FINANCIAL INC | 246K | 7.3M | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 242K | 7.2M | 新進 | 新進 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 233K | 6.9M | 新進 | 新進 |
| PARADIGM CAPITAL MANAGEMENT INC/NY | 229K | 6.8M | 新進 | 新進 |
| MACKENZIE FINANCIAL CORP | 227K | 6.8M | 新進 | 新進 |
| GLOBEFLEX CAPITAL L P | 222K | 6.6M | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 181 -4 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 181 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 21.9M · 96.7% |
| 合計季末市值 | 609M |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 2.6M |
|---|---|
| 與上期比 | +2.3% |
| 佔流通股數 | 11.52% |
| 日均成交量 | 337K |
| 回補天數 | 7.7 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 2.6M | +2.3% | 11.52% | 337K | 7.7 |
| 2026-08-14 | 2.6M | +8.5% | 11.26% | 427K | 6.0 |
| 2026-07-31 | 2.4M | -4.0% | 10.38% | 205K | 11.5 |
| 2026-07-15 | 2.4M | +0.2% | 10.81% | 233K | 10.5 |
| 2026-06-30 | 2.4M | +6.0% | 10.79% | 312K | 7.8 |
| 2026-06-15 | 2.3M | -2.4% | 10.18% | 212K | 10.9 |
| 2026-05-29 | 2.4M | +2.5% | 10.43% | 272K | 8.7 |
| 2026-05-15 | 2.3M | +26.2% | 10.18% | 486K | 4.7 |
| 2026-04-30 | 1.8M | +10.3% | 8.07% | 259K | 7.1 |
| 2026-04-15 | 1.7M | -1.0% | 7.31% | 233K | 7.1 |
| 2026-03-31 | 1.7M | -11.8% | 7.38% | 271K | 6.2 |
| 2026-03-13 | 1.9M | +8.5% | 8.38% | 268K | 7.1 |
| 2026-02-27 | 1.7M | -5.4% | 7.72% | 670K | 2.6 |
| 2026-02-13 | 1.8M | +1.0% | 8.16% | 230K | 8.1 |
| 2026-01-30 | 1.8M | -1.6% | 8.08% | 262K | 7.0 |
| 2026-01-15 | 1.9M | +5.0% | 8.21% | 368K | 5.0 |
| 2025-12-31 | 1.8M | -15.4% | 7.81% | 303K | 5.9 |
| 2025-12-15 | 2.1M | +12.7% | 9.24% | 395K | 5.3 |
| 2025-11-28 | 1.9M | +10.4% | 8.20% | 507K | 3.7 |
| 2025-11-14 | 1.7M | -8.4% | 7.43% | 1.0M | 1.6 |
| 2025-10-31 | 1.8M | -5.5% | 8.11% | 140K | 13.1 |
| 2025-10-15 | 1.9M | -0.9% | 8.58% | 161K | 12.1 |
| 2025-09-30 | 2.0M | -5.4% | 8.65% | 195K | 10.1 |
| 2025-09-15 | 2.1M | -2.6% | 9.15% | 206K | 10.1 |
| 2025-08-29 | 2.1M | -3.7% | 9.39% | 167K | 12.8 |
| 2025-08-15 | 2.2M | -3.4% | 9.75% | 338K | 6.5 |